Depression

The experts weighed in on a wide variety of psychiatric issues for the November 2023 issue of Psychiatric Times.

Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.

Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.

From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

What is new in research on anxiety symptoms and disorders?

From sleep disturbances in ADHD to psychotherapy for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

What is new in research on psychedelics?

"Evidence indicates that psychotherapy may yield greater durability of treatment gains than pharmacotherapy."

In this Special Report, let's re-evalute depression.

"During the past 5 years has gabapentin retained its position as one of the top 10 drugs prescribed in the United States."

As many as 30% of your patients will experience treatment-resistant depression...

Suicidal individuals with depression likely have diminished capacity to provide informed consent for treatment as well as low perceived need for help.

From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.

Gepirone, the first and only oral selective 5HT1a receptor agonist for the treatment of major depressive disorder in adults, is expected to arrive in early 2024.

Researchers performed a head-to-head trial of vortioxetine versus desvenalfaxine in patients with depression and partial response to SSRIs.

Researchers investigated associations between medications with potential depressive symptom adverse effects and the level of depressive symptoms in a large survey study. Here’s what they found.

Here are some updates from the world of psychiatry throughout the month of October.

What is new in research on TMS?

In this CME article, review literature on SRI-related bleeding complications in patients with GI bleeding, malignancy, perioperative settings, pregnancy, and hormonal therapy.

Does early improvement in insomnia predict response to pharmacotherapy in psychotic depression? Authors performed a secondary analysis of a randomized clinical trial.

From new research on treatment-resistant major depression to strategies for supporting trauma-affected refugee youth, here are highlights from the week in Psychiatric Times.

What is new in research on depression?

“Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray.”

The investigators also concluded that depression screening alone may not be sufficient to effectively identify suicide risk.